Supplementary Table S5 from the Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab Plus Chemotherapy in Triple-Negative Breast Cancer

Supplementary Table 5. Multivariable regression of pCR according to NGS-based IO score and TNBC subtypes in the RNA-Seq cohort. For TNBC subtypes LAR was taken as reference group.